



**THE ALLIANCE FOR EYE AND VISION RESEARCH  
(AEVR)**

*continues its series of educational briefings on  
breakthrough developments in eye and vision  
research funded by the National Eye Institute (NEI)*

**Please join us for a Luncheon Briefing**

***“Vision for the Future:  
Eye Imaging to Save and Restore Sight”***

**Tuesday, April 17, 2007**

**12:00 Noon – 1:15 pm**

**Senate Hart 902**

**Please R.S.V.P. to  
Dina Beaumont @ 202-530-4672 or [dina\\_beaumont@yr.com](mailto:dina_beaumont@yr.com)**

**Note: AEVR is a 501(c)3 Non-Profit Educational Foundation  
hosting this widely attended event with meal value less than \$50**

**AEVR Luncheon Briefing on Vision Research**  
**“Vision for the Future: Eye Imaging to Save and Restore Sight”**  
**Tuesday, April 17, 2007**  
**12 Noon -1:15 pm, Senate Hart 902**  
**R.S.V.P. to: 202-530-4672 or dina\_beaumont@yr.com**

**What is the focus of this briefing?**

The briefing will describe the new generation of non-invasive imaging technologies, including Optical Coherence Tomography (OCT), that are enabling practitioners to view key physiological structures within the eye to determine how changes over time may relate to eye disease and vision impairment. These devices produce cross-sectional images that reveal the layers of the retina (the light sensitive back of the eye) and its center portion, called the macula, which is vital for central vision. Changes over time in the retinal layers could indicate the onset of age-related macular degeneration (AMD), the leading cause of blindness—either in the “wet” form of the disease, where blood vessels grow abnormally, hemorrhage, and scar, or the “dry” form, where atrophy and degeneration lead to visual loss. By analyzing the optic nerve head, these devices can assess the early signs of glaucoma. They are also beneficial for the evaluation of cataract patients, pre- and post-operatively.

**Why are these visual imaging technologies important?**

The images from these devices are critical for the diagnosis, monitoring, and treatment of eye disease, as they provide quantitative measurements of changes in eye structures. If a treatment can be evaluated quantitatively, the greater its likelihood to be adopted into clinical practice. The dynamic environment created by the use of these new visual imaging tools affects the entire spectrum of eye care, including the basic and clinical vision research conducted by the National Eye Institute (NEI)/National Institutes of Health (NIH), product approval and coverage decisions for new treatments made by governmental agencies, and the clinical practice decisions made by physicians. These new quantitative measurement tools also enable vision research and eye care to meet the new paradigm for the 21<sup>st</sup> century medicine as described by NIH Director Dr. Elias Zerhouni—that which is preemptive, predictive, preventive and personalized.

**About the speaker...**

**Stephen J. Ryan, M.D.**, is the President of the Doheny Eye Institute and the Grace and Emery Beardsley Professor of Ophthalmology and served as the Dean of the Keck School of Medicine of the University of Southern California from 1991 to 2004.

**About the Alliance...**

The Alliance for Eye and Vision Research (AEVR) is a 501(c)3 non-profit foundation dedicated to education about the importance of federal funding for eye and vision research. AEVR is pleased to host this widely attended event, with a meal value of less than \$50.